![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
School of Pharmaceutical Sciences, Showa University, Tokyo, Japan (Y.Sh., H.S.); and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (M.H., Y.Su.)
A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported. In the present study, we examined the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-
-glucuronide (GEM-1-O-glu), on the uptake of CER by human organic anion transporting polypeptide 2 (OATP2)-expressing cells and its metabolism in cytochrome P450 expression systems. Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC50 values of 72 and 24 µM, respectively. They also inhibited the CYP2C8-mediated metabolism of CER with IC50 values of 28 and 4 µM, respectively, whereas M3 had no effects. GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metabolism of CER. The IC50 values of GEM and GEM-1-O-glu for the uptake and the metabolism of CER obtained in the present study were lower than their total, and not unbound, plasma concentrations. However, considering the possibly concentrated high unbound concentrations of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metabolism of CER appears to be the main mechanism for the clinically relevant drug-drug interaction. Previously reported clinical drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concentration-time curve of these statins, also supported our present conclusion.
Address correspondence to: Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp
This article has been cited by other articles:
|
|
 |
|
  A. Liu, A. D. Patterson, Z. Yang, X. Zhang, W. Liu, F. Qiu, H. Sun, K. W. Krausz, J. R. Idle, F. J. Gonzalez, et al. Fenofibrate Metabolism in the Cynomolgus Monkey using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics Drug Metab. Dispos., June 1, 2009; 37(6): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J. L. Stock, X. Liu, J. Shi, J. W. Van Deusen, D. A. DiMattia, R. G. Dullea, and S. M. de Morais Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds Drug Metab. Dispos., September 1, 2008; 36(9): 1840 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. He, W. Zhang, J.-H. Tu, J. Kirchheiner, Y. Chen, D. Guo, Q. Li, Z.-Y. Li, H. Chen, D.-L. Hu, et al. Hepatic Nuclear Factor 1{alpha} Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin Drug Metab. Dispos., August 1, 2008; 36(8): 1453 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Schoch, J. K. Yano, S. Sansen, P. M. Dansette, C. D. Stout, and E. F. Johnson Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID J. Biol. Chem., June 20, 2008; 283(25): 17227 - 17237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Albrecht, A. Unger, A. K. Nussler, and S. Laufer In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase Drug Metab. Dispos., May 1, 2008; 36(5): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tornio, M. Niemi, P. J. Neuvonen, and J. T. Backman Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone Drug Metab. Dispos., January 1, 2008; 36(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver Drug Metab. Dispos., November 1, 2007; 35(11): 2040 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J. Lin, T. Smolarek, and L. Tremaine P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice Drug Metab. Dispos., October 1, 2007; 35(10): 1725 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Noe, R. Portmann, M.-E. Brun, and C. Funk Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos., August 1, 2007; 35(8): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hallifax and J. B. Houston Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction Drug Metab. Dispos., August 1, 2007; 35(8): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Triplitt Drug Interactions of Medications Commonly Used in Diabetes Diabetes Spectr, October 1, 2006; 19(4): 202 - 211. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Lam, H. Okochi, Y. Huang, and L. Z. Benet IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY Drug Metab. Dispos., August 1, 2006; 34(8): 1336 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 Drug Metab. Dispos., July 1, 2006; 34(7): 1229 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS Drug Metab. Dispos., January 1, 2006; 34(1): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, A. W. Wolkoff, and M. E. Morris FLAVONOIDS AS A NOVEL CLASS OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP1B1 (OATP-C) MODULATORS Drug Metab. Dispos., November 1, 2005; 33(11): 1666 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chang, K. S. Pang, P. W. Swaan, and S. Ekins Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 Drug Metab. Dispos., April 1, 2005; 33(4): 537 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delaforge, A. Pruvost, L. Perrin, and F. Andre CYTOCHROME P450-MEDIATED OXIDATION OF GLUCURONIDE DERIVATIVES: EXAMPLE OF ESTRADIOL-17{beta}-GLUCURONIDE OXIDATION TO 2-HYDROXY-ESTRADIOL-17{beta}-GLUCURONIDE BY CYP 2C8 Drug Metab. Dispos., March 1, 2005; 33(3): 466 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky, R. S. Obach, E. A. Gaman, J.-P. R. Gleeson, and W. R. Proctor SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST Drug Metab. Dispos., March 1, 2005; 33(3): 413 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Walsky, E. A. Gaman, and R. S. Obach Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8 J. Clin. Pharmacol., January 1, 2005; 45(1): 68 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shitara, M. Hirano, Y. Adachi, T. Itoh, H. Sato, and Y. Sugiyama IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS Drug Metab. Dispos., December 1, 2004; 32(12): 1468 - 1475. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
